FDA Grants Rare Pediatric Designation for ALXN1840, Opening Path to Valuable Priority Review Voucher
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Monopar Therapeutics received Rare Pediatric Disease (RPD) designation from the FDA for its lead candidate, ALXN1840, for Wilson disease. This designation makes the company eligible for a Priority Review Voucher (PRV) upon potential NDA approval, which can be sold or used to expedite the review of a future drug. This follows highly positive Phase 3 data for ALXN1840 and an anticipated NDA submission in mid-2026, further de-risking the asset and adding a significant potential non-dilutive asset to the company.
At the time of this announcement, MNPR was trading at $94.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $633.5M. The 52-week trading range was $29.18 to $105.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.